Efficient induction of antitumor cytoxic T lymphocytes from a healthy donor using HLA-A2-restricted MAGE-3 peptide in vitro

Cancer Immunology Immunotherapy

Volumn 44, Issue 1, 1997, Pages 21-26

  Tanaka, Fumiaki ^a   Fujie, Tatsuo ^a   Go, Hiroki ^a   Baba, Kinya ^a   Mori, Masaki ^a   Takesako, Kazutoh ^b   Akiyoshi, Tsuyoshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b TAKARA SHUZO CO LTD   (Japan)

Author keywords

cytotoxic T lymphocytes; MAGE 3; peptide; tumor rejection antigen

Indexed keywords

HLA A2 ANTIGEN; MELANOMA ANTIGEN 3; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL; TUMOR REJECTION;

ANTIGENS, NEOPLASM; CELL DIVISION; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; PEPTIDES; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030951543     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050350     Document Type: Article

References (36)

1. Bakker AB, Marland G, Boer AJ de, Huijbens RJ, Danen EH, Adema GJ, Figdor CG (1995) Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 55:5330
2. Boon T, Cerottini JC, Van den Eynde B, Bruggen P van der, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337
3. Brasseur F, Rimoldi D, Liénard D, Lethé B, Carrel, S, Arienti F, Suter L, Vanwijivk R, Bourlond A, Humblet Y, Vacca A, Conese M, Lahaya T, Degiovanni R, Beauduin M, Saster X, Salamon E, Dréno B, Jager E, Knuth A, Chevreau C, Suciu S, Lachapelle J-M, Pouillart P, Parmiani G, Lejeune F, Cerottini J-C, Boon T, Marchand M (1995) Expression of MAGE genes in primary and mestatic cutaneous melanoma. Int J Cancer 63:375
4. Brichard V, Van Pel A, Wölffel T, De Plean E, Lethe B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489
5. Bruggen P van der, Traversari C, Chomez P, Lurquin C, De Plean E, Van Eynde B den, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643
6. Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038
7. Cells E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, Grey HM, Sette A, Serra HM (1994) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105
8. Chomczynnski PSN (1987) Single-step method of RNA isolation by acid guanidium thiocyanate-PhOH-chloroform extraction. Anal Biochem 162:156
9. Coulie PG, Weynants P, Lehmann F, Herman J. Brichard V. Wolfel T, Van Pel A, De Plean E, Brasseur F, Boon T (1993) Genes coding for tumor antigens recognized by human cytolytic T lymphocytes. J Immunother 14:104
10. Coulie PG, Brichard V, Van Pel A, Wölffel T, Schnider J, Tranersari C, Mattei S, De Plean E, Kurquin C, Szikora J-P, Renauld J-C, Boon T (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180:35
11. Dong RP, Kimura A, Okubo R, Shinagawa H, Tamai H, Nishimura Y, Sasazuki T (1992) HLA-A and DPB1 loci confer susceptibility to Graves' disease. Hum Immunol 35:165
12. Eura M, Ogi K, Chikamatsu K, Lee KD, Nakano K, Masuyama K, Itoh K, Ishikawa T (1995) Expression of the MAGE gene family in human head-and-neck squamous-cell carcinomas. Int J Cancer 64:304
13. Gaugler B, Van den Eynde B, Bruggen P van der, Romero P, Gaforlo JJ, De Plean E, Lethe B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytotoxic T lymphocytes. J Exp Med 179:921
14. Herman J, van der Bruggen P, Lueschert IF, Mandruzzato S, Romero P, Thonnard J, Fleischhauer K, Boon T, and Coulie PG (1996) A peptide encoded by human gene MAGE-3 and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Immunogenetics 4:377
15. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Murkherji B (1996) Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 56:2479
16. Inaba K, Metlay JP, Croeley MT, Steinman RM (1990) Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 172:631
17. Inoue H, Mori M, Honda M, Li J, Shibuta K, Mimori K, Ueo H, Akiyoshi T (1995) The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology 109:1522
18. Inoue H, Mori M, Li J, Mimori K, Honda M, Nakashima H, Mafune K, Tanaka Y, Akiyoshi T (1995) Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer 63:523
19. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA (1994) Cloning of the gene coding for a shared human melanoma antigen recogni/,ed by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91:3531
20. Kawakami Y, Eliyahu S, Delgedo CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458
21. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijk R, Humblet Y, Canon J-L. Laurent C, Naeyaert J-M, Plagne R, Deraemaeker R, Knuth A, Jager E, Brasseur F, Herman J, Coulie PG, Boon T (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883
22. Mori M, Inoue H, Miniori K, Shibuta K, Baba K, Nakashima H, Haraguchi M, Tsuji K, Ueo H, Barnard FD, Akiyoshi T (1996) Expression of MAGE genes in human colorectal carcinoma. Ann Surg 224:183
23. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J, Mauri F (1995) Enhancement of cytotoxic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGH-1 peptide loaded antigen presenting cell-based vaccine. Proe Natl Acad Sci USA 92:8078
24. Ledoux S, Rebai N, Dagenais A, Shaw IT, Nalbantoglu J, Sekaly RP, Cashman NR (1993) Amyloid precursor protein in peripheral mononuclear cells is up-regulated with cell activation. J Immunol 150:5566
25. Patard JJ, Brasseur F, Gil DS, Radvanyi F, Marchand M, Francois P, Abi AA, Van CP, Abbou CC, Chopin D, Boon T (1995) Expression of MAGE genes in transitional carcinomas of the urinary bladder. Int J Cancer 64:60
26. Plebanski M, Allsopp CE, Aidoo M, Reyburn H, Hill AV (1995) Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. Eur J Immunol 25:1783
27. Porgador A, Gilboa E (1995) Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182:255
28. Russo V, Traversari C, Verrecchia A, Mottolese M, Natali PG, Bordignon C (1995) Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer 64:216
29. Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawskami Y, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 55:4972
30. Salgaller ML, Weber JS, Koenig S, Yanneli JR, Rosenberg SA (1994) Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother 39:105
31. Spagnoli GC, Schaefer C, Willimann TE, Kocher T, Amoroso A, Juretic A. Zuber M, Luscher U, Harder F, Heberer M (1995) Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int J Cancer 64:309
32. Tokunaga K, Nakamura Y, Sakata K, Fujimori K, Ohkubo M, Sawada K, Sakiyama S (1987) Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res 47:5616
33. Toso JF, Oel C, Oshidari F, Tartglia J, Paoletti E, Lyerly HK, Tallb S, Weinhold KJ (1996) MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res 56:16
34. Traversari C, Bruggen P van der, Luescher IF, Lurquin C, Chomez, P. Van Pel A, De Piean E, Amar CA, Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytotoxic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453
35. Weynants P, Lethe B, Brasseur F, Marchand M, Boon T (1994) Expression of mage genes by non-small-cell lung carcinomas. Int J Cancer 56:826
36. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87